Amarex logo

  • Home
  • News and Resources
  • News
  • Taiwan President Tsai Ing-wen Meets Amarex President & CEO Dr. Kazempour At BIO Asia-Taiwan 2019, and Dr. Kazempour Keynotes for Cell & Gene Therapy

Taiwan President Tsai Ing-wen Meets Amarex President & CEO Dr. Kazempour At BIO Asia-Taiwan 2019, and Dr. Kazempour Keynotes for Cell & Gene Therapy

Germantown, MD, USA (August 22, 2019) – Amarex Clinical Research, LLC is pleased to announce that Taiwan President Tsai Ing-wen attended the opening ceremony for BIO Asia-Taiwan on July 25, 2019 to show her support for Taiwanese expertise and innovation in biotechnology R&D. Amarex Taiwan exhibited services at the conference and Dr. Kazem Kazempour, as well as the company’s COO, Dr. Chia-Hua Maggie Ho, were honored to meet President Tsai at Amarex’s exhibit. The support of the Taiwanese government to the biotech industry in Taiwan indicates a distinct commitment that the people of Taiwan have to this industry, and Amarex is privileged to be a part of this growing piece of Taiwan’s economy. Dr. Kazempour stated to President Tsai that, “Amarex has established an office in Taipei and employs talented, well-educated, young Taiwanese staff members. Our organization is dedicated to helping local biotech and pharmaceutical companies bring their clinical products to the U.S. market.”

The opening ceremony was filmed by Taiwan Television (TTV) News Channel. To view this event, visit

At BIO Asia-Taiwan 2019, Amarex Taiwan’s President & CEO, Dr. Kazempour, gave a keynote presentation in the area of Cell & Gene Therapy, which addressed clinical trial design challenges for cellular therapy products. Dr. Kazempour emphasized that CMC can be a challenge for cell therapy approval but this is always overcome with documentation of proper steps. Moreover, he recommended regulatory and clinical opportunities to consider, including newly-formed expedited programs for cell therapy and adaptive trial design to address the complexities associated with cell therapy product development.

About Amarex Clinical Research

Amarex is a global, full service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs (FDA Applications and meetings, Applications to International Health Authorities, GxP Compliance Audits), Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management, Medical Monitoring, Safety and Pharmacovigilance, and General Consulting. Amarex can take your product through the entire approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval application. Join our growing list of clients with approved products. Amarex provides high quality and cost efficient services. For more information visit

Patrick J. Burke
Business Development

20201 Century Blvd., Fourth Floor
Germantown, MD 20874 USA
301 528 7000

Contact Us

Book a meeting or send us a message to talk to one of our experts.